display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 1st line (L1)la/mBC - HR-positive - 2nd line (L2)
IGF-1R inhibitors
dalotuzumab plus ridaforolimus plus exemestane MK-8669-064
ganitumab plus endocrine therapy QUILT-2.015

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons